Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

value-based pricing

This page shows the latest value-based pricing news and features for those working in and with pharma, biotech and healthcare.

Novartis secures US approval - and payers’ blessing – for $2m gene therapy Zolgensma

Novartis secures US approval - and payers’ blessing – for $2m gene therapy Zolgensma

We have used value based pricing frameworks to price Zolgensma at around 50% less than multiple established benchmarks including the 10-year current cost of chronic SMA therapy. ... bound of ICER's value-based price benchmark range.".

Latest news

  • Senate grilling makes pharma CEOs squirm, but give little ground Senate grilling makes pharma CEOs squirm, but give little ground

    a cap on Medicare out of pocket payments, and supported value-based payments as a future pricing model. ... grilling. Despite being a longstanding critic of pharma’s pricing, Grassley has also indicated he wants to work with the sector on reform if

  • Roche buys gene therapy specialist Spark for $4.3bn Roche buys gene therapy specialist Spark for $4.3bn

    Spark has already made some efforts towards value-based pricing for Luxturna based on clinical outcome in order to win reimbursement, but there is likely to be a number of twists ... Boston-based Spark has been in friendly rivalry with its neighbour

  • Making a list and checking it twice… Making a list and checking it twice…

    And about making it more difficult to distribute fentanyl and oxycodone-based drugs. ... How long have we heard about value-based pricing and risk-sharing as possible panaceas to the unsustainability of health system costs?

  • UK government tables bill on medicine pricing reforms UK government tables bill on medicine pricing reforms

    The ABPI acknowledges the need for clarity on pricing on older medicines and has been calling on the government to take action on the issue of significant price rises in a ... The proposed system would appear to draw a line under the UK's flirtation with

  • European pharma considering medicine pricing shakeup European pharma considering medicine pricing shakeup

    EFPIA will later this month discuss proposals for a value-based pricing system.  . ... In the future, we believe we can contribute to more sustainable healthcare systems by developing new pricing models, such as outcomes-based, or value-based

More from news
Approximately 12 fully matching, plus 89 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    From R&D to marketing, we’re happy to anticipate the future when our predictions are based on good science. ... Scientists, however, are always interested in the null hypothesis. It is interesting that, for example, firms and their customers have

  • Transforming clinical trial data into a long-term asset Transforming clinical trial data into a long-term asset

    Throughout the product life cycle, good practice in archiving can prove to be of value when dealing with pharmacovigilance, value-based pricing and reimbursement, as well as in the search for ... Many millions of pounds might well have been spent on

  • Communicating with payers to improve patient access Communicating with payers to improve patient access

    Develop ICPs to benchmark health outcomes. A key part of patient-centricity is developing strategies that add value to the touchpoints of the patients' journeys. ... Utilise real-world data to demonstrate outcomes. With payers increasingly imposing

  • Digital Business Models Digital Business Models

    Cloud-based real-world big data and real-time patient monitoring will drive value analytics, providing insights into patient outcomes that will drive successful value-based pricing. ... The life sciences industry should establish a data supply chain that

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    of a new drug pricing system, known as value-based pricing (VBP). ... Speaking to PME for its UK Pricing, Value and Access supplement, Burstow said: “Really, we've gained no insight or learning from the dozens of drugs being funded within the scheme.

More from intelligence
Approximately 3 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....

Quick links